Macrolides and ketolides

Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics

Volumn , Issue , 2014, Pages 257-278

  Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

AUC MIC; K tolides; Macrolides; Tissue distribution

Indexed keywords

EID: 84910010052     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-75613-4_11     Document Type: Chapter

References (135)

1. Alferova I.V., Vostrov SN, Portnoy YA et al (2005) Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations. Int J Antimicrob Agents 26:197-204
2. Ambrose PG, Bhavnani SM, Rubino CM et al (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86
3. Amsden GW (2001) Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 18(Suppl 1):S11-S15
4. Amsden GW, Nafziger AN, Foulds G. (1999) Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother 43:163-165
5. Andes DR, Okusanya OO, Forrest A et al (2010) Pharmacokinetic-pharmacodynamic (PK-PD) analysis of Solithromycin against Streptococcus pneumoniae using data from a murine-lung infection model. In: 50th Interscience conference on antimicrobial agents and chemotherapy (ICAAC), Boston, MA A1-688
6. Bahal N, Nahata M.C. (1992) The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 26:46-55
7. Barcia-Macay M., Seral C, Mingeot-Leclercq MP et al (2006) Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 50:841-851
8. Blackman HJ, Yoneda C, Dawson CR et al (1977) Antibiotic susceptibility of Chlamydia trachomatis. Antimicrob Agents Chemother 12:673-677
9. Blais J, Beauchamp D, Chamberland S. (1994) Azithromycin uptake and intracellular accumulation by Toxoplasma gondii-infected macrophages. J Antimicrob Chemother 34:371-382
10. Bosnar M, Kelneric Z, Munic V et al (2005) Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 49: 2372-2377
11. Boswell FJ, Andrews JM, Wise R. (1998) Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 41:149-153
12. Bright GM, Nagel AA, Bordner J et al (1988) Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J Antibiot (Tokyo) 41:1029-1047
13. Brogden RN, Peters D.H. (1994) Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 48:599-616
14. Bryskier A (2000) Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 6:661-669
15. Carbon C (1998) Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis 27:28-32
16. Carlier MB, Zenebergh A, Tulkens P.M. (1987) Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 20(Suppl B): 47-56
17. Carlier MB, Garcia-Luque I, Montenez JP et al (1994) Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int J Tissue React 16:211-220
18. Carryn S, Van Bambeke F, Mingeot-Leclercq MP et al (2002) Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother 46:2095-2103
19. Carryn S, Chanteux H, Seral C et al (2003) Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am 17:615-634
20. Chantot JF, Bryskier A, Gasc J.C. (1986) Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo) 39:660-668
21. Conte JE J.r., Golden JA, Kipps J et al (2004) Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin. Antimicrob Agents Chemother 48:3508-3515
22. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10
23. Craig WA, Kiem S, Andes D.R. (2002) Free drug 24-Hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin. In: 42d Interscience conference on antimicrobial agents and chemotherapy, San Diego, CA A-1264
24. de Duve C., de Barsy T, Poole B et al (1974) Commentary. Lysosomotropic agents. Biochem Pharmacol 23:2495-2531
25. Denis A, Agouridas C, Auger JM et al (1999) Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorg Med Chem Lett 9:3075-3080
26. Di Paolo A., Barbara C, Chella A et al (2002) Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol Res 46:545-550
27. Djokic S, Kobrehel G, Lazarevski G. (1987) Erythromycin series. XII. Antibacterial in vitro evaluation of 10-dihydro-10-deoxo-11-azaerythromycin A: synthesis and structure-activity relationship of its acyl derivatives. J Antibiot (Tokyo) 40:1006-1015
28. Dornbusch K, Olofsson C, Holm S. (1999) Postantibiotic effect and postantibiotic sub-mic effect of dirithromycin and erythromycin against respiratory tract pathogenic bacteria. APMIS 107:505-513
29. Douthwaite S (2001) Structure-activity relationships of ketolides vs. macrolides. Clin Microbiol Infect 7(Suppl 3):11-17
30. Douthwaite S, Champney W.S. (2001) Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother 48 (Suppl T1):1-8
31. Drago L, De Vecchi E, Nicola L et al (2005) Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens. APMIS 113:655-663
32. Ehnhage A, Rautiainen M, Fang AF et al (2008) Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis. Int J Antimicrob Agents 31:561-566
33. Fang AF, Palmer JN, Chiu AG et al (2009) Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis. Int J Antimicrob Agents 34:67-71
34. Fernandes PB, Bailer R, Swanson R et al (1986) In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother 30:865-873
35. Firsov AA, Zinner SH, Vostrov SN et al (2002) Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. J Antimicrob Chemother 49:113-119
36. Foulds G, Shepard RM, Johnson R.B. (1990) The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25(Suppl A):73-82
37. Foulds G, Chan KH, Johnson JT et al (1991) Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 10:853-856
38. Fraschini F, Scaglione F, Demartini G. (1993) Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 25:189-204
39. Freeman CD, Nightingale CH, Nicolau DP et al (1994) Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob Agents Chemother 38:2449-2451
40. Furneri PM, Nicoletti G. (1991) Macrolides: present and future. An appraisal of in-vitro activity and pharmacokinetic behavior. J Chemother 3(Suppl 1):24-27
41. Furuie H, Saisho Y, Yoshikawa T et al (2010) Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. Antimicrob Agents Chemother 54:866-870
42. Garcia I, Pascual A, Ballesta S et al (2003) Accumulation and activity of cethromycin (ABT-773) within human polymorphonuclear leucocytes. J Antimicrob Chemother 52:24-28
43. Gattringer R, Urbauer E, Traunmuller F et al (2004) Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. Antimicrob Agents Chemother 48:4650-4653
44. Gehanno P, Sultan E, Passot V et al (2003) Telithromycin (HMR 3647) achieves high and sustained concentrations in tonsils of patients undergoing tonsillectomy. Int J Antimicrob Agents 21: 441-445
45. Girard AE, Girard D, Retsema J.A. (1990) Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J Antimicrob Chemother 25(Suppl A):61-71
46. Gladue RP, Bright GM, Isaacson RE et al (1989) In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33:277-282
47. Gotfried MH, Danziger LH, Rodvold K.A. (2003) Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. J Antimicrob Chemother 52:450-456
48. Guay DR, Gustavson LE, Devcich KJ et al (2001) Pharmacokinetics and tolerability of extendedrelease clarithromycin. Clin Ther 23:566-577
49. Hand WL, Hand D.L. (2001) Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents 18:419-425
50. Hoffman HL, Klepser ME, Ernst EJ et al (2003) Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 47:739-746
51. Homma T, Hori T, Ohshiro M et al (2010) In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae. Antimicrob Agents Chemother 54:4300-4305
52. Horwitz MA, Silverstein S.C. (1983) Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin. J Clin Invest 71:15-26
53. Hwang CK, Duffield J, Chiu YH et al (2008) SAR of 11, 12-carbamate macrolides/ketolides linked with 1,4-substituted-[1,2,3]-triazoles. In: 48th Interscience conference on antimicrobial agents and chemotherapy (ICAAC) & 46th annual meeting of the infectious diseases society of America (IDSA), Washington, DC F1-3973
54. Jiang LJ, Wang M, Or Y.S. (2009) Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. Antimicrob Agents Chemother 53:1786-1792
55. Kadota J, Ishimatsu Y, Iwashita T et al (2002) Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers. Antimicrob Agents Chemother 46:917-921
56. Kanazawa Y, Kuramata T. (1976) Evaluation of midecamycin sensitivity disc (author's transl). Jpn J Antibiot 29:178-183
57. Kawaharajo K, Sekizawa Y, Inoue M. (1981) In vitro and in vivo antibacterial activity of 9,3''-Di-oacetyl midecamycin (Mom), a new macrolide antibiotic. J Antibiot (Tokyo) 34:436-442
58. Kays MB, Lisek CR, Denys G.A. (2007) Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology. Int J Antimicrob Agents 29:289-294
59. Kearney BP, Aweeka F.T. (1999) The penetration of anti-infectives into the central nervous system. Neurol Clin 17:883-900
60. Kellow WF, Lepper MH, Plauts S et al (1955) Spiramycin in the treatment of infection. Antibiot Annu 3:658-666
61. Khair OA, Andrews JM, Honeybourne D et al (2001) Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 47:837-840
62. Kikuchi E, Yamazaki K, Kikuchi J et al (2008) Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. Respirology 13:221-226
63. Kim MK, Zhou W, Tessier PR et al (2002) Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother 46:3185-3192
64. Kirst HA, Sides G.D. (1989) New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 33:1413-1418
65. Kuehnel TS, Schurr C, Lotter K et al (2005) Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis. J Antimicrob Chemother 55:591-594
66. Labro MT, Abdelghaffar H, Babin-Chevaye C (2004) Interaction of the new ketolide ABT-773 (cethromycin) with human polymorphonuclear neutrophils and the phagocytic cell line PLB-985 in vitro. Antimicrob Agents Chemother 48:1096-1104
67. Lawrence LE (2001) ABT-773 (Abbott laboratories). Curr Opin Investig Drugs 2:766-772
68. Lemaire S, Van Bambeke F, Tulkens P.M. (2009) Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother 53:3734-3743
69. Lippert C, Gbenado S, Qiu C et al (2005) The bioequivalence of telithromycin administered orally as crushed tablets versus tablets swallowed whole. J Clin Pharmacol 45:1025-1031
70. Liu P, Allaudeen H, Chandra R et al (2007) Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 51:103-109
71. Lodise TP, Preston S, Bhargava V et al (2005) Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis 52:45-52
72. Lucchi M, Damle B, Fang A et al (2008) Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin. J Antimicrob Chemother 61:884-891
73. Mandell GL, Coleman E. (2001) Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 45:1794-1798
74. Massey EH, Kitchell B, Martin LD et al (1970) Erythromycylamine. Tetrahedron Lett 2:157-160
75. Massey EH, Kitchell BS, Martin LD et al (1974) Antibacterial activity of 9(S)-erythromycylaminealdehyde condensation products. J Med Chem 17:105-107
76. McDonald PJ, Pruul H. (1991) Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 10:828-833
77. McGuire JM, Bunch RL, Anderson RC et al (1952) Ilotycin, a new antibiotic. Antibiot Chemother 2:281-283
78. Mikamo H, Ninomiya M, Tamaya T. (2003) Penetration of oral telithromycin into female genital tissues. J Infect Chemother 9:358-360
79. Montenez JP, Van Bambeke F, Piret J et al (1999) Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol Appl Pharmacol 156:129-140
80. Mor N, Vanderkolk J, Heifets L. (1994) Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. Pharmacotherapy 14:100-104
81. Morimoto S, Takahashi Y, Watanabe Y et al (1984) Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J Antibiot (Tokyo) 37: 187-189
82. Muller-Serieys C., Soler P, Cantalloube C et al (2001) Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother 45:3104-3108
83. Munic V, Kelneric Z, Mikac L et al (2010) Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci 41:86-95
84. Muto C, Liu P, Chiba K et al (2011) Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease. J Antimicrob Chemother 66:165-174
85. Namour F, Wessels DH, Pascual MH et al (2001) Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 45:170-175
86. Namour F, Sultan E, Pascual MH et al (2002) Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration. J Antimicrob Chemother 49:1035-1038
87. Neuhauser MM, Prause JL, Danziger LH et al (2003) In vitro bactericidal activities of ABT-773 against ermB strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 47:1132-1134
88. Nitta K, Yano K, Miyamoto F et al (1967) A new antibiotic, josamycin. II. Biological studies. J Antibiot (Tokyo) 20:181-187
89. Noreddin AM, Roberts D, Nichol K et al (2002) Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 46:4029-4034
90. Noreddin AM, El Khatib WF, Aolie J et al (2009) Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae. Int J Infect Dis 13:483-487
91. Odenholt I, Lowdin E, Cars O. (2001) Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 45:23-29
92. Odenholt-Tornqvist I., Lowdin E, Cars O. (1995) Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 39:221-226
93. Okusanya OO, Bhavnani SM, Forrest A et al (2010) Pharmacokinetic-pharmacodynamic target attainment analysis supporting Solithromycin (CEM-101) Phase 2 dose selection. In: 50th Interscience conference on antimicrobial agents and chemotherapy (ICAAC), Boston, MA A1-692
94. Omoto S, Iwamatsu K, Inouye S et al (1976) Modifications of a macrolide antibiotic midecamycin (SF-837). I. Synthesis and structure of 9,3''-diacetylmidecamycin. J Antibiot (Tokyo) 29:536-548
95. Or YS, Clark RF, Wang S et al (2000) Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. J Med Chem 43:1045-1049
96. Pachot JI, Botham RP, Haegele KD et al (2003) Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci 6:1-12
97. Pai MP, Momary KM, Rodvold K.A. (2006) Antibiotic drug interactions. Med Clin North Am 90:1223-1255
98. Pascual A, Rodriguez-Bano J, Ballesta S et al (1997) Azithromycin uptake by tissue cultured epithelial cells. J Antimicrob Chemother 39:293-295
99. Pascual A, Ballesta S, Garcia I et al (2001) Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells. Clin Microbiol Infect 7:65-69
100. Peters DH, Clissold S.P. (1992) Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 44:117-164
101. Pletz MW, Preechachatchaval V, Bulitta J et al (2003) ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. Antimicrob Agents Chemother 47:1129-1131
102. Puri SK, Lassman H.B. (1987) Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother 20(Suppl B):89-100
103. Rodvold KA, Gotfried MH, Danziger LH et al (1997) Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 41:1399-1402
104. Rodvold KA, Gotfried MH, Still JG et al (2012) Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother 56(10):5076-5081
105. Sakakibara H, Okekawa O, Fujiwara T et al (1981) Acyl derivatives of 16-membered macrolides. I. Synthesis and biological properties of 3"-O-propionylleucomycin A5 (TMS-19-Q). J Antibiot (Tokyo) 34:1001-1010
106. Sandberg A, Hessler JH, Skov RL et al (2009) Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. Antimicrob Agents Chemother 53:1874-1883
107. Schentag JJ, Ballow C.H. (1991) Tissue-directed pharmacokinetics. Am J Med 91:5S-11S
108. Seral C, Carryn S, Tulkens PM et al (2003a) Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother 51:1167-1173
109. Seral C, Michot JM, Chanteux H et al (2003b) Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob Agents Chemother 47: 1047-1051
110. Shakeri-Nejad K., Stahlmann R. (2006) Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 7:639-651
111. Shi J, Montay G, Bhargava V.O. (2005) Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 44:915-934
112. Shinkai M, Henke MO, Rubin B.K. (2008) Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 117:393-405
113. Still JG, Schranz J, Degenhardt TP et al (2011) Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 55:1997-2003
114. Swainston HT, Keam S.J. (2007) Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs 67:773-792
115. Tessier PR, Kim MK, Zhou W et al (2002) Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 46:1425-1434
116. Tessier PR, Mattoes HM, Dandekar PK et al (2005) Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 49:188-194
117. Togami K, Chono S, Seki T et al (2010a) Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. Drug Dev Ind Pharm 36:861-866
118. Togami K, Chono S, Seki T et al (2010b) Intracellular pharmacokinetics of telithromycin, a ketolide antibiotic, in alveolar macrophages. J Pharm Pharmacol 62:71-75
119. Traunmuller F, Fille M, Thallinger C et al (2009) Multiple-dose pharmacokinetics of telithromycin in peripheral soft tissues. Int J Antimicrob Agents 34:72-75
120. Treyaprasert W, Schmidt S, Rand KH et al (2007) Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents 29:263-270
121. Van Bambeke F., Barcia-Macay M, Lemaire S et al (2006) Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr Opin Drug Discov Devel 9:218-230
122. Van Bambeke F., Harms JM, Van Laethem Y et al (2008) Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opin Pharmacother 9:267-283
123. Vazifeh D, Preira A, Bryskier A et al (1998) Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 42:1944-1951
124. Veber B, Vallee E, Desmonts JM et al (1993) Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia. J Antimicrob Chemother 32:473-482
125. Vesga O, Bonnat C, Craig W.A. (1997) In vivo pharmacodynamic activity of HMR 3647, a new ketolide. In: 37th Interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada F-255
126. Villa P, Sassella D, Corada M et al (1988) Toxicity, uptake, and subcellular distribution in rat hepatocytes of roxithromycin, a new semisynthetic macrolide, and erythromycin base. Antimicrob Agents Chemother 32:1541-1546
127. Wang G, Niu D, Qiu YL et al (2004) Synthesis of novel 6,11-O-bridged bicyclic ketolides via a palladium-catalyzed bis-allylation. Org Lett 6:4455-4458
128. Wildfeuer A, Haberreiter A. (1997) Intracellular activity of azithromycin against Mycobacterium avium complex in human macrophages. Arzneimittelforschung 47:866-868
129. Woosley LN, Castanheira M, Jones R.N. (2010) CEM-101 activity against Gram-positive organisms. Antimicrob Agents Chemother 54:2182-2187
130. Zeitlinger M, Wagner CC, Heinisch B. (2009) Ketolides-the modern relatives of macrolides: the pharmacokinetic perspective. Clin Pharmacokinet 48:23-38
131. Zhanel GG, Dueck M, Hoban DJ et al (2001) Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 61:443-498
132. Zhanel GG, Walters M, Noreddin A et al (2002) The ketolides: a critical review. Drugs 62: 1771-1804
133. Zhanel GG, DeCorby M, Noreddin A et al (2003) Pharmacodynamic activity of azithromycin against macrolide-susceptible and - resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52:83-88
134. Zhanel GG, Johanson C, Laing N et al (2005) Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrob Agents Chemother 49:1943-1948
135. Zhang Y, Wang X, Lin X et al (2010) High azithromycin loading powders for inhalation and their in vivo evaluation in rats. Int J Pharm 395:205-214